Danavorexton
- Generic Name
- Danavorexton
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32N2O5S
- CAS Number
- 2114324-48-8
- Unique Ingredient Identifier
- 1QMD83K4YN
A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 41
- Registration Number
- NCT05814016
- Locations
- πΊπΈ
Helen Keller Hospital, Sheffield, Alabama, United States
πΊπΈMayo Clinic - PPDS - Hospital, Phoenix, Arizona, United States
πΊπΈUCSD, La Jolla, California, United States
A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 13
- Registration Number
- NCT05180890
- Locations
- π¦πΊ
Adelaide Institute for Sleep Health (AISH), Flinders University, Adelaide, Australia
A Study of Danavorexton in Anesthetized Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 28
- Registration Number
- NCT05025397
- Locations
- πΊπΈ
Endeavor Clinical Trials, San Antonio, Texas, United States
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04091438
- Locations
- πΊπΈ
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
π―π΅SOUSEIKAI PS Clinic, Hakata-ku, Fukuoka-Ken, Japan
πΊπΈPulmonary Associates Clinical Trials, Glendale, Arizona, United States
Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04091425
- Locations
- πΊπΈ
Pulmonary Associates Clinical Trials, Glendale, Arizona, United States
πΊπΈWright Clinical Research, Alabaster, Alabama, United States
πΊπΈPreferred Research Partners, Inc., Little Rock, Arkansas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 57
- Registration Number
- NCT03748979
- Locations
- π―π΅
PS Clinic, Fukuoka, Japan
π―π΅Sumida Hospital, Sumida-ku, Tokyo, Japan
π―π΅Hakata Clinic, Fukuoka, Japan
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT03522506
- Locations
- πΊπΈ
PRA Health Sciences, Salt Lake City, Utah, United States
Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy
- Conditions
- Healthy Participants and Patients With Narcolepsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 58
- Registration Number
- NCT03332784
- Locations
- π―π΅
PS Clinic, Fukuoka, Japan
π―π΅Hakata Clinic, Fukuoka, Japan
π―π΅Sumida Hospital, Sumida-ku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.